Omnimmune Holdings, Inc. is engaged in the provision of cancer therapeutic, diagnostic and prognostic technologies. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2007-12-19. The firm is the holding company of Omnimmune Corp. Omnimmune has acquired licensed rights to diagnostic and platform monoclonal antibody technologies. Omnimmune’s hCGß and related technologies, which are protected through an expanding intellectual property portfolio, have been developed at institutions including Columbia University of New York, New York (Columbia), The Allegheny-Singer Research Institute of the West Penn Allegheny Health System, Pittsburgh, Pennsylvania (Allegheny) and The Institute Gustave Roussy, Paris, France (IGR).
Follow-Up Questions
Omnimmune Holdings Inc 'in CEO'su kimdir?
Travis McPhee 2007 'den beri şirketle birlikte olan Omnimmune Holdings Inc 'in Chief Executive Officer 'ıdır.
OMMH hissesinin fiyat performansı nasıl?
OMMH 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
Omnimmune Holdings Inc için ana iş temaları veya sektörler nelerdir?
Omnimmune Holdings Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
